Raffa Wealth Management’s Aldeyra Therapeutics ALDX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$2.33K Hold
1,897
– – ﹤0.01% 791
2026
Q2
$4.04K Hold
1,897
– – ﹤0.01% 643
2026
Q1
$3.21K Hold
1,897
– – ﹤0.01% 638
2025
Q4
$9.8K Hold
1,897
– – ﹤0.01% 382
2025
Q3
$9.9K Hold
1,897
– – ﹤0.01% 366
2025
Q2
$7.27K Hold
1,897
– – ﹤0.01% 441
2025
Q1
$10.9K Hold
1,897
– – ﹤0.01% 299
2024
Q4
$9.47K Buy
+1,897
New +$9.7K ﹤0.01% 337

Other funds holding ALDX

Raffa Wealth Management's ALDX Position: Q3 2026 in Review

Raffa Wealth Management held its Aldeyra Therapeutics (ALDX) position steady in Q3 2026 at 1,897 shares worth $2.33K. The position accounts for ﹤0.01% of the portfolio, ranked #791.

Raffa Wealth Management first reported a position in ALDX in Q4 2024 and has held it in 8 quarters since. The position peaked at $10.9K in Q1 2025. 97 funds tracked by Wall St. Rank hold ALDX as of Q3 2026.

  • Raffa Wealth Management held 1,897 shares of Aldeyra Therapeutics worth $2.33K as of Q3 2026.
  • Raffa Wealth Management left its Aldeyra Therapeutics share count unchanged in Q3 2026.
  • Aldeyra Therapeutics made up ﹤0.01% of Raffa Wealth Management's portfolio in Q3 2026, its #791 holding.
  • Raffa Wealth Management first reported a position in Aldeyra Therapeutics in Q4 2024 and has held it in 8 quarters since.
  • Raffa Wealth Management's Aldeyra Therapeutics position peaked at $10.9K in Q1 2025.
  • 97 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q3 2026.

Based on Raffa Wealth Management's 13F filing for Q3 2026, filed 16 Nov 2026.